NasdaqGS:ABCLLife Sciences
Is AbCellera (ABCL) Quietly Rewriting Its Investment Story With Cash Reserves And Advancing Trials?
AbCellera Biologics recently outlined its evolution toward becoming a mid- to late-stage biotech at the 2026 KeyBanc Capital Markets Healthcare Forum, highlighting a clinical pipeline that includes ABCL635 in Phase 2 for non-hormonal hot flashes and ABCL575 in Phase 1 for immunological diseases.
The company also underscored a cash position of roughly US$700 million and a three-year funding runway, a combination that may give it unusual flexibility to keep advancing its programs and...